Alterations in brain structure and function after chemotherapy for cancer

Future Neurology

Volumn 7, Issue 4, 2012, Pages 443-452

  Pomykala, Kelsey L ^a   Silverman, Daniel H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chemobrain; chemotherapy; cognitive dysfunction; cognitive impairment; PET

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; DEXMETHYLPHENIDATE; DONEPEZIL; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; FLUOXETINE; METHOTREXATE; METHYLPHENIDATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ATTENTION; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEHAVIOR THERAPY; BRAIN DISEASE; BRAIN FUNCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVOR; COGNITIVE DEFECT; COGNITIVE THERAPY; DISEASE COURSE; DNA DAMAGE; DRUG MEGADOSE; EXECUTIVE FUNCTION; FUNCTIONAL ASSESSMENT; GENETIC VARIABILITY; GRAY MATTER; HUMAN; LANGUAGE DISABILITY; LEARNING; MALIGNANT NEOPLASTIC DISEASE; MEMORY DISORDER; MENTAL CAPACITY; MENTAL PERFORMANCE; NERVE CELL LESION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PATHOGENESIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN DEFECT; PSYCHOMOTOR DISORDER; PSYCHOPATHY; RECALL; REHABILITATION CARE; REVIEW; TREATMENT RESPONSE; VISION;

EID: 84863749119     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.38     Document Type: Review

References (87)

1. American Cancer Society. Cancer Facts & Figures 2011 Pamphet. American Cancer Society, GA, USA (2011). Provides important statistical information about cancer incidence and the number of survivors.
2. Silverman DH, Davidson I. Your Brain After Chemo: A Practical Guide to Lifting the Fog and Getting Back Your Focus. Da Capo Lifelong Books, Cambridge, MA, USA (2009).
3. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP. Either called "Chemobrain" or "Chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J. Pain Symptom Manage. 41(1), 126-139 (2011).
4. Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J. 14(6), 396-400 (2008).
5. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol. Rev. 18(2), 121-131 (2008).
6. Tchen N, Juffs HG, Downie FP et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 21(22), 4175-4183 (2003).
7. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 26(7), 955-969 (2004).
8. Hurria A, Goldfarb S, Rosen C et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res. Treat. 98(3), 343-348 (2006).
9. Hurria A, Rosen C, Hudis C et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J. Am. Geriatr. Soc. 54(6), 925-931 (2006).
10. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14), 3348-3356 (2010).
11. Vearncombe KJ, Rolfe M, Andrew B, Pachana NA, Wright M, Beadle G. Cognitive effects of chemotherapy-induced menopause in breast cancer. Clin. Neuropsychol. 25(8), 1295-1313 (2011).
12. Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J. Clin. Oncol. 30(10), 1080-1086 (2012). Examines the largest cohort of breast cancer survivors to date and uniquely analyzes deficiencies that are present over 20 years after treatment.
13. Silverman DHS, Castellon SA, Ganz PA. Cognitive dysfunction associated with chemotherapy for breast cancer. Future Neurol. 2(3), 271-277 (2007).
14. Silverman D, Dy C, Castellon S et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res. Treat. 103(3), 303-311 (2007). First study to demonstrate regional brain changes in metabolism in chemotherapy-treated breast cancer patients.
15. Hurria A, Hurria A, Zuckerman E et al. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J. Am. Geriatr. Soc. 54(7), 1119-1124 (2006).
16. Ferguson RJ, Ahles TA, Saykin AJ et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16(8), 772-777 (2007).
17. Kohli S, Griggs JJ, Roscoe JA et al. Self-reported cognitive impairment in patients with cancer. J. Oncol. Pract. Am. Soc. Clin. Oncol. 3(2), 54-59 (2007).
18. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin. Breast Cancer 8(1), 88-91 (2008).
19. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 17(2), 122-130 (2008).
20. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 18(2), 134-143 (2009).
21. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res. Treat. 116(1), 113-123 (2009).
22. Reid-Arndt SA, Yee A, Perry MC, Hsieh C. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J. Psychosoc. Oncol. 27(4), 415-434 (2009).
23. Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psychooncology 18(7), 775-782 (2009).
24. Ahles TA, Saykin AJ, McDonald BC et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J. Clin. Oncol. 28(29), 4434-4440 (2010). This prospective longitudinal study is particularly well-designed, includes a relatively large number of subjects and both cancer survivors without chemotherapy and healthy controls. It also examines potential risk factors for post-chemotherapy brain.
25. Debess J, Riis JO, Engebjerg MC, Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res. Treat. 121(1), 91-100 (2010).
26. McDonald B, Conroy S, Ahles T, West J, Saykin A. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res. Treat. 123(3), 819-828 (2010). First prospective longitudinal study to use MRI to demonstrate decreases in gray matter volume in chemotherapy-treated breast cancer patients.
27. Deprez S, Amant F, Yigit R et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum. Brain Mapp. 32(3), 480-493 (2011).
28. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support. Care Cancer 19(10), 1647-1656 (2011).
29. Biglia N, Bounous VE, Malabaila A et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur. J. Cancer Care 21(4), 485-492 (2012).
30. Deprez S, Amant F, Smeets A et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J. Clin. Oncol. 30(3), 274-281 (2012). First prospective longitudinal study to use diffusion tensor imaging to demonstrate alterations in white matter structure in chemotherapy-treated breast cancer patients.
31. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma? Cancer 101(3), 466-475 (2004).
32. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer 100(11), 2292-2299 (2004).
33. Kesler SR, Bennett FC, Mahaffey ML, Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin. Cancer Res. 15(21), 6665-6673 (2009).
34. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J. Neuropsychiatry Clin. Neurosci. 22(1), 48-54 (2010).
35. De Ruiter MB, Reneman L, Boogerd W et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum. Brain Mapp. doi:10.1002/hbm.21422 (2011) (Epub ahead of print).
36. De Ruiter MB, Reneman L, Boogerd W et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum. Brain Mapp. 32(8), 1206-1219 (2011).
37. Kesler SR, Kent JS, O'hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch. Neurol. 68(11), 1447-1453 (2011).
38. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer 7(3), 192-201 (2007). This innovative review summarizes several candidate mechanisms for post-chemotherapy cognitive dysfunction in detail.
39. 13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med. 28(12), 1844-1852 (1987).
40. 11C-labelled BCNU and SarCNU in gliomas studied by PET. J. Neurooncol. 10(1), 47-55 (1991).
41. 18F-fluoropaclitaxel. J. Nucl. Med. 46(11), 1866-1871 (2005).
42. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol. 5(7), 22 (2006).
43. Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: so if they don't divide what's to repair? Mutat. Res. 614(1-2), 24-36 (2007).
44. Schroder CP, Wisman GB, De Jong S et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br. J. Cancer 84(10), 1348-1353 (2001).
45. Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med. Hypotheses 67(2), 212-215 (2006).
46. Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr. Mol. Med. 5(2), 197-203 (2005).
47. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 50(12), 2041-2056 (2002).
48. Scherling CS, Collins B, Mackenzie J, Bielajew C, Smith A. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an fMRI study. Front. Hum. Neurosci. 5, 122 (2011).
49. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J. Clin. Exp. Neuropsychol. 34(5), 543-560 (2012).
50. Vardy J, Booth C, Pond GR et al. Cytokine levels in patients with colorectal cancer and breat cancer and their relationship to fatigue and cognitive function. J. Clin. Oncol. 25(18s) 9027 (2007).
51. Dodds C, Allison J. Postoperative cognitive deficit in the elderly surgical patient. Br. J. Anaesth. 81(3), 449-462 (1998).
52. Dijkstra JB, Houx PJ, Jolles J. Cognition after major surgery in the elderly: test performance and complaints. Br. J. Anaesth. 82(6), 867-874 (1999).
53. Monk TG, Weldon BC, Garvan CW et al. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology 108(1), 18-30 (2008).
54. Sapolsky RM. A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. J. Neurosci. 5(5), 1228-1232 (1985).
55. Mcewen BS, Magarinos AM. Stress effects on morphology and function of the hippocampus. Ann. NY Acad. Sci. 821, 271-284 (1997).
56. Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav. Neurosci. 113(3), 420-430 (1999).
57. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat. Rev. 20(2), 191-214 (1994).
58. O'Shaughnessy JA, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin. Breast Cancer 5(6), 439-446 (2005).
59. Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit. Rev. Oncol. Hematol. 57(2), 175-182 (2006).
60. Iconomou G, Koutras A, Karaivazoglou K et al. Effect of epoetin a therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur. J. Cancer Care (Engl.). 17(6), 535-541 (2008).
61. Fan HG, Park A, Xu W et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2), 156-161 (2009).
62. Fardell JE, Vardy J, Johnston IN, Winocur G. Chemotherapy and cognitive impairment: treatment options. Clin. Pharmacol. Ther. 90(3), 366-376 (2011). Does an excellent job of summarizing treatment options for post-chemotherapy cognitive dysfunction and their support in current literature.
63. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J. Psychiatry Neurosci. 30(2), 100-107 (2005).
64. Mar Fan H, Clemons M, Xu W et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6), 577-583 (2008).
65. Lower EE, Fleishman S, Cooper A et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J. Pain Symptom Manage. 38(5), 650-662 (2009).
66. Lundorff LE, Jonsson BH, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat. Med. 23(8), 731-738 (2009).
67. Kohli S, Fisher SG, Tra Y et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12), 2605-2616 (2009).
68. Winocur G, Binns MA, Tannock I. Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology 61(8), 1222-1228 (2011).
69. Elbeltagy M, Mustafa S, Umka J et al. Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. Behav. Brain Res. 208(1), 112-117 (2010).
70. Lyons L, Elbeltagy M, Umka J et al. Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology 215(1), 105-115 (2011).
71. Anderson ND, Winocur G, Palmer H. Principles of cognitive rehabilitation. In: The Handbook of Clinical Neuropsychology. Gurd J, Kischka U, Marshall J (Eds). Oxford University Press, London, UK, 50-77 (2010).
72. Ferguson RJ, Mcdonald BC, Rocque MA et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 21(2), 176-186 (2012).
73. Ercoli LM, Castellon SA, Kwan L et al. Effects of a cognitive rehabilitation pilot program for breast cancer survivors. Presented at: International Cognition and Cancer Task Force Conference. Paris, France, 15-17 March 2012.
74. Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J. Psychosoc. Oncol. 27(2), 274-296 (2009).
75. Hermelink K, Untch M, Lux MP et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109(9), 1905-1913 (2007).
76. Cimprich B, Reuter-Lorenz P, Nelson J et al. Prechemotherapy alterations in brain function in women with breast cancer. J. Clin. Exp. Neuropsychol. 32(3), 324-331 (2010).
77. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann. Oncol. 19(4), 623-629 (2008).
78. Mustafa S, Walker A, Bennett G, Wigmore PM. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur. J. Neurosci. 28(2), 323-330 (2008).
79. Seigers R, Schagen SB, Beerling W et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav. Brain Res. 186(2), 168-175 (2008).
80. Seigers R, Schagen SB, Coppens CM et al. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav. Brain Res. 201(2), 279-284 (2009).
81. Seigers R, Pourtau L, Schagen SB et al. Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. Brain Res. Bull. 81(4-5), 472-476 (2010).
82. Seigers R, Timmermans J, Van Der Horn HJ et al. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav. Brain Res. 207(2), 265-272 (2010).
83. Fardell JE, Vardy J, Logge W, Johnston I. Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacol. Biochem. Behav. 97(2), 333-339 (2010).
84. Mondie CM, Vandergrift KA, Wilson CL, Gulinello ME, Weber ET. The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Behav. Brain Res. 209(1), 66-72 (2010).
85. Yang M, Kim JS, Song MS et al. Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits. Neurobiol. Learn Memory 93(4), 487-494 (2010).
86. Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci. Amp. Biobehav. Rev. 35(3), 729-741 (2011).
87. WHO. Cancer fact sheet No. 297. www.who.int/mediacentre/factsheets/fs297/ en